Therapeutic potential of selectin antagonists in psoriasis

Bibliography

• FARBER E, M., NALL ML: Epidemiology: natural history and genetics. In: Psoriasis, Roenigk HH, Maibach HI (Eds), Marcel Dekker, New York, USA (1998):107-158.
   Google Scholar
• RAHMAN P, ELDER JT: Genetic epidemiology of psoriasis and psoriatic arthritis. Ann. Rheum. Dis. (2005) 64(Suppl. 2):37-39 (Discussion 40-31).
   Web of Science ®Google Scholar
• BARKER JN: Genetic aspects of psoriasis. Clin. Exp. Dermatol. (2001) 26(4):321-325.
   PubMed Web of Science ®Google Scholar
• PASIC A, GRAHOVAC B, LIPOZENCIC J et al.: The genetics of psoriasis. Acta Dermatovenerol. Croat. (2004) 12(1):18-25.
   PubMedGoogle Scholar
• SZCZERKOWSKA-DOBOSZ A: Human leukocyte antigens as psoriasis inheritance and susceptibility markers. Arch. Immunol. Ther. Exp. (Warsz) (2005) 53(5):428-433.
   PubMed Web of Science ®Google Scholar
• SCHON MP, BOEHNCKE WH: Psoriasis. N. Engl. J. Med. (2005) 352(18):1899-1912.
   PubMed Web of Science ®Google Scholar
• KORMEILI T, LOWE NJ, YAMAUCHI PS: Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; US experiences. Br. J. Dermatol. (2004) 151(1):3-15.
   PubMed Web of Science ®Google Scholar
• DE JONG EM: The course of psoriasis. Clin. Dermatol. (1997) 15(5):687-692.
   PubMed Web of Science ®Google Scholar
• ESPINOZA LR, CUELLAR ML, SILVEIRA LH: Psoriatic arthritis. Curr. Opin. Rheumatol. (1992) 4(4):470-478.
   PubMedGoogle Scholar
• CHRISTOPHERS E: Psoriasis-epidemiology and clinical spectrum. Clin. Exp. Dermatol. (2001) 26(4):314-320.
   PubMed Web of Science ®Google Scholar
• KUPPER TS, FUHLBRIGGE RC: Immune surveillance in the skin: mechanisms and clinical consequences. Nat. Rev. Immunol. (2004) 4(3):211-222.
   PubMed Web of Science ®Google Scholar
• NICKOLOFF BJ: The immunologic and genetic basis of psoriasis. Arch. Dermatol. (1999) 135(9):1104-1110.
   PubMed Web of Science ®Google Scholar
• KRUEGER JG, BOWCOCK A: Psoriasis pathophysiology: current concepts of pathogenesis. Ann. Rheum. Dis. (2005) 64(Suppl. 2):30-36.
   Web of Science ®Google Scholar
• GODIC A: New approaches to psoriasis treatment. A review. Acta Dermatoven APA (2004) 13(2):50-57.
   Google Scholar
• GREAVES MW, WEINSTEIN GD: Treatment of psoriasis. N. Engl. J. Med. (1995) 332(9):581-588.
   PubMed Web of Science ®Google Scholar
• LEBWOHL M, TING PT, KOO JY: Psoriasis treatment: traditional therapy. Ann. Rheum. Dis. (2005) 64(Suppl. 2):83-86.
   Web of Science ®Google Scholar
• WINTERFIELD LS, MENTER A, GORDON K, GOTTLIEB A: Psoriasis treatment: current and emerging directed therapies. Ann. Rheum. Dis. (2005) 64(Suppl. 2):87-90 (Discussion 91-92).
   Web of Science ®Google Scholar
• LOFHOLM PW: The psoriasis treatment ladder: a clinical overview for pharmacists. US Pharmacist (2000).
   Google Scholar
• KATZ HI: Topical corticosteroids. Dermatol. Clin. (1995) 13(4):805-815.
   PubMed Web of Science ®Google Scholar
• WOLF-HENNING B, FRIEDRICH M, MROWIETZ U et al.: The role of biologics into the management of psoriasis: a consensus paper by the Psoriasis Study Group, Arbeitsgemeinschaft Dermatologische Forschung. J. Dtsch Dermatol. Ges. (2003) 1(8):620-628.
   PubMedGoogle Scholar
• SHAFIQ N, MALHOTRA S, PANDHI P et al.: Pilot trial: pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int. J. Dermatol. (2005) 44(4):328-333.
   PubMed Web of Science ®Google Scholar
• WEINBERG JM, BOTTINO CJ, LINDHOLM J, BUCHHOLZ R: Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept. J. Drugs Dermatol. (2005) 4(5):544-555.
   PubMedGoogle Scholar
• SAUDER DN, MAMELAK AJ: Understanding the new clinical landscape for psoriasis: a comparative review of biologics. J. Cutan. Med. Surg. (2004) 8(4):205-212.
   PubMed Web of Science ®Google Scholar
• MILLER GT, HOCHMAN PS, MEIER W et al.: Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J. Exp. Med. (1993) 178(1):211-222.
   PubMed Web of Science ®Google Scholar
• DEDRICK RL, WALICKE P, GAROVOY M: Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody. Transpl. Immunol. (2002) 9(2-4):181-186.
   PubMed Web of Science ®Google Scholar
• PAPP K, BISSONNETTE R, KRUEGER JG et al.: The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J. Am. Acad. Dermatol. (2001) 45(5):665-674.
   PubMed Web of Science ®Google Scholar
• LEBWOHL M, TYRING SK, HAMILTON TK et al.: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. (2003) 349(21):2004-2013.
   PubMed Web of Science ®Google Scholar
• BOEHNCKE WH, SCHON MP, GIROMOLOMI G et al.: Leukocyte extravasation as a target for anti-inflammatory therapy – which molecule to choose? Exp. Dermatol. (2005) 14(1):70-80.
   PubMed Web of Science ®Google Scholar
• TERAJIMA S, HIGAKI M, IGARASHI Y, NOGITA T, KAWASHIMA M: An important role of tumor necrosis factor-α in the induction of adhesion molecules in psoriasis. Arch. Dermatol. Res. (1998) 290(5):246-252.
   PubMed Web of Science ®Google Scholar
• GROVES RW, ALLEN MH, BARKER JN, HASKARD DO, MacDONALD DM: Endothelial leucocyte adhesion molecule-1 (ELAM-1) expression in cutaneous inflammation. Br. J. Dermatol. (1991) 124(2):117-123.
   PubMed Web of Science ®Google Scholar
• VEALE D, ROGERS S, FITZGERALD O: Immunolocalization of adhesion molecules in psoriatic arthritis, psoriatic and normal skin. Br. J. Dermatol. (1995) 132(1):32-38.
   PubMed Web of Science ®Google Scholar
• BEVILACQUA MP, NELSON RM: Selectins. J. Clin. Invest. (1993) 91(2):379-387.
   PubMed Web of Science ®Google Scholar
• BEVILACQUA MP, STENGELIN S, GIMBRONE MA Jr, SEED B: Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science (1989) 243(4895):1160-1165.
   PubMed Web of Science ®Google Scholar
• SIGMUNDSDOTTIR H, JOHNSTON A, GUDJONSSON JE, BJARNASON B, VALDIMARSSON H: Methotrexate markedly reduces the expression of vascular E-selectin, cutaneous lymphocyte-associated antigen and the numbers of mononuclear leucocytes in psoriatic skin. Exp. Dermatol. (2004) 13(7):426-434.
   PubMed Web of Science ®Google Scholar
• RICCIERI V, SPADARO A, TACCARI E et al.: [Immunohistochemical analysis of the expression of main adhesion molecules and tumor necrosis factors in the synovial membrane of psoriatic arthritis]. Reumatismo (2003) 55(3):164-170.
   PubMedGoogle Scholar
• McEVER RP, BECKSTEAD JH, MOORE KL, MARSHALL-CARLSON L, BAINTON DF: GMP-140, a platelet α-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J. Clin. Invest. (1989) 84(1):92-99.
   PubMed Web of Science ®Google Scholar
• BONFANTI R, FURIE BC, FURIE B, WAGNER DD: PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood (1989) 73(5):1109-1112.
   PubMed Web of Science ®Google Scholar
• STENBERG PE, McEVER RP, SHUMAN MA, JACQUES YV, BAINTON DF: A platelet α-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J. Cell Biol. (1985) 101(3):880-886.
   PubMed Web of Science ®Google Scholar
• BERMAN CL, YEO EL, WENCEL-DRAKE JD et al.: A platelet α granule membrane protein that is associated with the plasma membrane after activation. Characterization and subcellular localization of platelet activation-dependent granule-external membrane protein. J. Clin. Invest. (1986) 78(1):130-137.
   PubMed Web of Science ®Google Scholar
• HATTORI R, HAMILTON KK, FUGATE RD, McEVER RP, SIMS PJ: Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J. Biol. Chem. (1989) 264(14):7768-7771.
   PubMed Web of Science ®Google Scholar
• MICHELSON AD, BARNARD MR, HECHTMAN HB et al.: In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc. Natl. Acad. Sci. USA (1996) 93(21):11877-11882.
   PubMed Web of Science ®Google Scholar
• KUIJPERS TW, RALEIGH M, KAVANAGH T et al.: Cytokine-activated endothelial cells internalize E-selectin into a lysosomal compartment of vesiculotubular shape. A tubulin-driven process. J. Immunol. (1994) 152(10):5060-5069.
   PubMed Web of Science ®Google Scholar
• GREEN SA, SETIADI H, McEVER RP, KELLY RB: The cytoplasmic domain of P-selectin contains a sorting determinant that mediates rapid degradation in lysosomes. J. Cell Biol. (1994) 124(4):435-448.
   PubMed Web of Science ®Google Scholar
• SMEETS EF, DE VRIES T, LEEUWENBERG JF et al.: Phosphorylation of surface E-selectin and the effect of soluble ligand (sialyl Lewisx) on the half-life of E-selectin. Eur. J. Immunol. (1993) 23(1):147-151.
   PubMed Web of Science ®Google Scholar
• SUBRAMANIAM M, KOEDAM JA, WAGNER DD: Divergent fates of P- and E-selectins after their expression on the plasma membrane. Mol. Biol. Cell (1993) 4(8):791-801.
   PubMed Web of Science ®Google Scholar
• GRIFFIN JD, SPERTINI O, ERNST TJ et al.: Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors. J. Immunol. (1990) 145(2):576-584.
   PubMed Web of Science ®Google Scholar
• JUTILA MA, ROTT L, BERG EL, BUTCHER EC: Function and regulation of the neutrophil MEL-14 antigen in vivo: comparison with LFA-1 and MAC-1. J. Immunol. (1989) 143(10):3318-3324.
   PubMed Web of Science ®Google Scholar
• KISHIMOTO TK, JUTILA MA, BERG EL, BUTCHER EC: Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors. Science (1989) 245(4923):1238-1241.
   Google Scholar
• SMALLEY DM, LEY K: L-selectin: mechanisms and physiological significance of ectodomain cleavage. J. Cell Mol. Med. (2005) 9(2):255-266.
   PubMed Web of Science ®Google Scholar
• SALLUSTO F, LENIG D, FORSTER R, LIPP M, LANZAVECCHIA A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 401(6754):708-712.
   PubMed Web of Science ®Google Scholar
• FOXALL C, WATSON SR, DOWBENKO D et al.: The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis(x) oligosaccharide. J. Cell Biol. (1992) 117(4):895-902.
   PubMed Web of Science ®Google Scholar
• ZAK I, LEWANDOWSKA E, GNYP W: Selectin glycoprotein ligands. Acta Biochim. Pol. (2000) 47(2):393-412.
   PubMed Web of Science ®Google Scholar
• SOMERS WS, TANG J, SHAW GD, CAMPHAUSEN RT: Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLe(X) and PSGL-1. Cell (2000) 103(3):467-479.
   PubMed Web of Science ®Google Scholar
• FUHLBRIGGE RC, KIEFFER JD, ARMERDING D, KUPPER TS: Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature (1997) 389(6654):978-981.
   PubMed Web of Science ®Google Scholar
• ROSSITER H, VAN REIJSEN F, MUDDE GC et al.: Skin disease-related T cells bind to endothelial selectins: expression of cutaneous lymphocyte antigen (CLA) predicts E-selectin but not P-selectin binding. Eur. J. Immunol. (1994) 24(1):205-210.
   PubMed Web of Science ®Google Scholar
• BERG EL, YOSHINO T, ROTT LS et al.: The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1. J. Exp. Med. (1991) 174(6):1461-1466.
   PubMed Web of Science ®Google Scholar
• BUTCHER EC: Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell (1991) 67(6):1033-1036.
   PubMed Web of Science ®Google Scholar
• McINTYRE TM, PRESCOTT SM, WEYRICH AS, ZIMMERMAN GA: Cell–cell interactions: leukocyte–endothelial interactions. Curr. Opin. Hematol. (2003) 10(2):150-158.
   PubMed Web of Science ®Google Scholar
• SIMON SI, GREEN CE: Molecular mechanics and dynamics of leukocyte recruitment during inflammation. Ann. Rev. Biomed. Eng. (2005) 7:151-185.
   PubMed Web of Science ®Google Scholar
• KUBES P, KERFOOT SM: Leukocyte recruitment in the microcirculation: the rolling paradigm revisited. News Physiol. Sci. (2001) 16:76-80.
   PubMedGoogle Scholar
• LEY K, KANSAS GS: Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation. Nat. Rev. Immunol. (2004) 4(5):325-335.
   PubMed Web of Science ®Google Scholar
• KUNKEL EJ, CHOMAS JE, LEY K: Role of primary and secondary capture for leukocyte accumulation in vivo. Circ. Res. (1998) 82(1):30-38.
   PubMed Web of Science ®Google Scholar
• SPERANDIO M, SMITH ML, FORLOW SB et al.: P-selectin glycoprotein ligand-1 mediates L-selectin-dependent leukocyte rolling in venules. J. Exp. Med. (2003) 197(10):1355-1363.
   PubMed Web of Science ®Google Scholar
• GREEN CE, PEARSON DN, CAMPHAUSEN RT, STAUNTON DE, SIMON SI: Shear-dependent capping of L-selectin and P-selectin glycoprotein ligand 1 by E-selectin signals activation of high-avidity β2-integrin on neutrophils. J. Immunol. (2004) 172(12):7780-7790.
   PubMed Web of Science ®Google Scholar
• CROCKETT-TORABI E: Selectins and mechanisms of signal transduction. J. Leukoc. Biol. (1998) 63(1):1-14.
   PubMed Web of Science ®Google Scholar
• BRENNER B, GULBINS E, SCHLOTTMANN K et al.: L-selectin activates the Ras pathway via the tyrosine kinase p56lck. Proc. Natl. Acad. Sci. USA (1996) 93(26):15376-15381.
   PubMed Web of Science ®Google Scholar
• BRENNER B, GULBINS E, BUSCH GL et al.: L-selectin regulates actin polymerisation via activation of the small G-protein Rac2. Biochem. Biophys. Res. Commun. (1997) 231(3):802-807.
   PubMed Web of Science ®Google Scholar
• SIMON SI, CHERAPANOV V, NADRA I et al.: Signaling functions of L-selectin in neutrophils: alterations in the cytoskeleton and colocalization with CD18. J. Immunol. (1999) 163(5):2891-2901.
   PubMed Web of Science ®Google Scholar
• LORENZON P, VECILE E, NARDON E et al.: Endothelial cell E- and P-selectin and vascular cell adhesion molecule-1 function as signaling receptors. J. Cell Biol. (1998) 142(5):1381-1391.
   PubMed Web of Science ®Google Scholar
• LAUDANNA C, CONSTANTIN G, BARON P et al.: Sulfatides trigger increase of cytosolic free calcium and enhanced expression of tumor necrosis factor-α and interleukin-8 mRNA in human neutrophils. Evidence for a role of L-selectin as a signaling molecule. J. Biol. Chem. (1994) 269(6):4021-4026.
   PubMed Web of Science ®Google Scholar
• DING Z, ISSEKUTZ TB, DOWNEY GP, WADDELL TK: L-selectin stimulation enhances functional expression of surface CXCR4 in lymphocytes: implications for cellular activation during adhesion and migration. Blood (2003) 101(11):4245-4252.
   PubMed Web of Science ®Google Scholar
• DUNSTAN RW, ROSSER EJ Jr: Does a condition like human pityriasis rosea occur in pigs? Am. J. Dermatopathol. (1986) 8(1):86-89.
   PubMed Web of Science ®Google Scholar
• MASON KV, HALLIWELL RE, McDOUGAL BJ: Characterization of lichenoid-psoriasiform dermatosis of springer spaniels. J. Am. Vet. Med. Assoc. (1986) 189(8):897-901.
   PubMed Web of Science ®Google Scholar
• JAYO MJ, ZANOLLI MD, JAYO JM: Psoriatic plaques in Macaca fascicularis. Vet. Pathol. (1988) 25(4):282-285.
   PubMed Web of Science ®Google Scholar
• LOWE NJ, BREEDING J, KEAN C, COHN ML: Psoriasiform dermatosis in a rhesus monkey. J. Invest. Dermatol. (1981) 76(2):141-143.
   PubMed Web of Science ®Google Scholar
• BEAMER WG, PELSUE SC, SHULTZ LD, SUNDBERG JP, BARKER JE: The flaky skin (fsn) mutation in mice: map location and description of the anemia. Blood (1995) 86(8):3220-3226.
   PubMedGoogle Scholar
• SUNDBERG JP, BOGGESS D, SUNDBERG BA, BEAMER WG, SHULTZ LD: Epidermal dendritic cell populations in the flaky skin mutant mouse. Immunol. Invest. (1993) 22(5):389-401.
   PubMed Web of Science ®Google Scholar
• SCHON M, BEHMENBURG C, DENZER D, SCHON MP: Pathogenic function of IL-1 β in psoriasiform skin lesions of flaky skin (fsn/fsn) mice. Clin. Exp. Immunol. (2001) 123(3):505-510.
   PubMed Web of Science ®Google Scholar
• ROTHNAGEL JA, GREENHALGH DA, WANG XJ et al.: Transgenic models of skin diseases. Arch. Dermatol. (1993) 129(11):1430-1436.
   PubMed Web of Science ®Google Scholar
• BOEHNCKE WH: Psoriasis in the animal model. Hautarzt (1997) 48(10):707-713.
   PubMed Web of Science ®Google Scholar
• JAMIESON T, COOK DN, NIBBS RJ et al.: The chemokine receptor D6 limits the inflammatory response in vivo. Nat. Immunol. (2005) 6(4):403-411.
   PubMed Web of Science ®Google Scholar
• ZENZ R, EFERL R, KENNER L et al.: Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature (2005) 437(7057):369-375.
   PubMed Web of Science ®Google Scholar
• XIA YP, LI B, HYLTON D et al.: Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood (2003) 102(1):161-168.
   PubMed Web of Science ®Google Scholar
• DETMAR M, BROWN LF, SCHON MP et al.: Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J. Invest. Dermatol. (1998) 111(1):1-6.
   PubMed Web of Science ®Google Scholar
• BOEHNCKE WH: The psoriasis SCID mouse model: a tool for drug discovery? Ernst Schering Res Found Workshop (2005) (50):213-234.
   PubMedGoogle Scholar
• BOYMAN O, HEFTI HP, CONRAD C et al.: Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-α. J. Exp. Med. (2004) 199(5):731-736.
   PubMed Web of Science ®Google Scholar
• DAM TN, KANG S, NICKOLOFF BJ, VOORHEES JJ: 1α,25-dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice. J. Invest. Dermatol. (1999) 113(6):1082-1089.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO T, MATSUUCHI M, KATAYAMA I, NISHIOKA K: Repeated subcutaneous injection of staphylococcal enterotoxin B-stimulated lymphocytes retains epidermal thickness of psoriatic skin-graft onto severe combined immunodeficient mice. J. Dermatol. Sci. (1998) 17(1):8-14.
   PubMed Web of Science ®Google Scholar
• CHU A, HONG K, BERG EL, EHRHARDT RO: Tissue specificity of E- and P-selectin ligands in Th1-mediated chronic inflammation. J. Immunol. (1999) 163(9):5086-5093.
   PubMed Web of Science ®Google Scholar
• ERDMANN I, SCHEIDEGGER EP, KOCH FK et al.: Fucosyltransferase VII-deficient mice with defective E-, P-, and L-selectin ligands show impaired CD4+ and CD8+ T cell migration into the skin, but normal extravasation into visceral organs. J. Immunol. (2002) 168(5):2139-2146.
   PubMed Web of Science ®Google Scholar
• SUBRAMANIAM M, SAFFARIPOUR S, WATSON SR et al.: Reduced recruitment of inflammatory cells in a contact hypersensitivity response in P-selectin-deficient mice. J. Exp. Med. (1995) 181(6):2277-2282.
   PubMed Web of Science ®Google Scholar
• STAITE ND, JUSTEN JM, SLY LM, BEAUDET AL, BULLARD DC: Inhibition of delayed-type contact hypersensitivity in mice deficient in both E-selectin and P-selectin. Blood (1996) 88(8):2973-2979.
   PubMed Web of Science ®Google Scholar
• BINNS RM, WHYTE A, LICENCE ST et al.: The role of E-selectin in lymphocyte and polymorphonuclear cell recruitment into cutaneous delayed hypersensitivity reactions in sensitized pigs. J. Immunol. (1996) 157(9):4094-4099.
   PubMed Web of Science ®Google Scholar
• SILBER A, NEWMAN W, SASSEVILLE VG et al.: Recruitment of lymphocytes during cutaneous delayed hypersensitivity in nonhuman primates is dependent on E-selectin and vascular cell adhesion molecule 1. J. Clin. Invest. (1994) 93(4):1554-1563.
   PubMed Web of Science ®Google Scholar
• HIRATA T, FURIE BC, FURIE B: P-, E-, and L-selectin mediate migration of activated CD8+ T lymphocytes into inflamed skin. J. Immunol. (2002) 169(8):4307-4313.
   PubMed Web of Science ®Google Scholar
• WAKITA H, TAKIGAWA M: E-selectin and vascular cell adhesion molecule-1 are critical for initial trafficking of helper-inducer/memory T cells in psoriatic plaques. Arch. Dermatol. (1994) 130(4):457-463.
   PubMed Web of Science ®Google Scholar
• PETZELBAUER P, POBER JS, KEH A, BRAVERMAN IM: Inducibility and expression of microvascular endothelial adhesion molecules in lesional, perilesional, and uninvolved skin of psoriatic patients. J. Invest. Dermatol. (1994) 103(3):300-305.
   PubMed Web of Science ®Google Scholar
• DAS PK, DE BOER OJ, VISSER A et al.: Differential expression of ICAM-1, E-selectin and VCAM-1 by endothelial cells in psoriasis and contact dermatitis. Acta Derm. Venereol. Suppl. (Stockh.) (1994) 186:21-22.
   PubMedGoogle Scholar
• DE BOER OJ, WAKELKAMP IM, PALS ST et al.: Increased expression of adhesion receptors in both lesional and non-lesional psoriatic skin. Arch. Dermatol. Res. (1994) 286(6):304-311.
   PubMed Web of Science ®Google Scholar
• CHONG BF, MURPHY JE, KUPPER TS, FUHLBRIGGE RC: E-selectin, thymus- and activation-regulated chemokine/CCL17, and intercellular adhesion molecule-1 are constitutively coexpressed in dermal microvessels: a foundation for a cutaneous immunosurveillance system. J. Immunol. (2004) 172(3):1575-1581.
   PubMed Web of Science ®Google Scholar
• KOWALZICK L, NEUBER K, WEICHENTHAL M, KOHLER I, RING J: Elevated serum-soluble ELAM-1 levels in patients with severe plaque-type psoriasis. Arch. Dermatol. Res. (1994) 286(7):414-416.
   PubMed Web of Science ®Google Scholar
• KRASOWSKA D, PIETRZAK A, LECEWICZ-TORUN B: Serum level of sELAM-1 in psoriatic patients correlates with disease activity. J. Eur. Acad. Dermatol. Venereol. (1999) 12(2):140-142.
   PubMed Web of Science ®Google Scholar
• CZECH W, SCHOPF E, KAPP A: Soluble E-selectin in sera of patients with atopic dermatitis and psoriasis-correlation with disease activity. Br. J. Dermatol. (1996) 134(1):17-21.
   PubMed Web of Science ®Google Scholar
• SZEPIETOWSKI J, WASIK F, BIELICKA E, NOCKOWSKI P, NOWOROLSKA A: Soluble E-selectin serum levels correlate with disease activity in psoriatic patients. Clin. Exp. Dermatol. (1999) 24(1):33-36.
   PubMed Web of Science ®Google Scholar
• LUDWIG RJ, SCHULTZ JE, BOEHNCKE WH et al.: Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. J. Invest. Dermatol. (2004) 122(3):830-836.
   PubMed Web of Science ®Google Scholar
• INAOKI M, SATO S, SHIMADA Y et al.: Decreased expression levels of L-selectin on subsets of leucocytes and increased serum L-selectin in severe psoriasis. Clin. Exp. Immunol. (2000) 122(3):484-492.
   PubMed Web of Science ®Google Scholar
• KUNSTFELD R, LECHLEITNER S, GROGER M, WOLFF K, PETZELBAUER P: HECA-452+ T cells migrate through superficial vascular plexus but not through deep vascular plexus endothelium. J. Invest. Dermatol. (1997) 108(3):343-348.
   PubMed Web of Science ®Google Scholar
• BORGES E, PENDL G, EYTNER R et al.: The binding of T cell-expressed P-selectin glycoprotein ligand-1 to E- and P-selectin is differentially regulated. J. Biol. Chem. (1997) 272(45):28786-28792.
   PubMed Web of Science ®Google Scholar
• PICKER LJ, KISHIMOTO TK, SMITH CW, WARNOCK RA, BUTCHER EC: ELAM-1 is an adhesion molecule for skin-homing T cells. Nature (1991) 349(6312):796-799.
   PubMed Web of Science ®Google Scholar
• KIEFFER JD, FUHLBRIGGE RC, ARMERDING D et al.: Neutrophils, monocytes, and dendritic cells express the same specialized form of PSGL-1 as do skin-homing memory T cells: cutaneous lymphocyte antigen. Biochem. Biophys. Res. Commun. (2001) 285(3):577-587.
   PubMed Web of Science ®Google Scholar
• RENKONEN J, TYNNINEN O, HAYRY P, PAAVONEN T, RENKONEN R: Glycosylation might provide endothelial zip codes for organ-specific leukocyte traffic into inflammatory sites. Am. J. Pathol. (2002) 161(2):543-550.
   PubMed Web of Science ®Google Scholar
• TU L, DELAHUNTY MD, DING H, LUSCINSKAS FW, TEDDER TF: The cutaneous lymphocyte antigen is an essential component of the L-selectin ligand induced on human vascular endothelial cells. J. Exp. Med. (1999) 189(2):241-252.
   PubMed Web of Science ®Google Scholar
• LECHLEITNER S, KUNSTFELD R, MESSERITSCH-FANTA C, WOLFF K, PETZELBAUER P: Peripheral lymph node addressins are expressed on skin endothelial cells. J. Invest. Dermatol. (1999) 113(3):410-414.
   PubMed Web of Science ®Google Scholar
• RUDDLE NH: Lymphoid neo-organogenesis: lymphotoxin’s role in inflammation and development. Immunol. Res. (1999) 19(2-3):119-125.
   PubMed Web of Science ®Google Scholar
• ROSEN SD: Ligands for L-selectin: homing, inflammation, and beyond. Ann. Rev. Immunol. (2004) 22:129-156.
   PubMed Web of Science ®Google Scholar
• DANNO K, KAJI A, MOCHIZUKI T: Alterations in ICAM-1 and ELAM-1 expression in psoriatic lesions following various treatments. J. Dermatol. Sci. (1996) 13(1):49-55.
   PubMed Web of Science ®Google Scholar
• CAI JP, HARRIS K, FALANGA V, TAYLOR JR, CHIN YH: UVB therapy decreases the adhesive interaction between peripheral blood mononuclear cells and dermal microvascular endothelium, and regulates the differential expression of CD54, VCAM-1, and E-selectin in psoriatic plaques. Br. J. Dermatol. (1996) 134(1):7-16.
   PubMedGoogle Scholar
• THORNHILL MH, HASKARD DO: IL-4 regulates endothelial cell activation by IL-1, tumor necrosis factor, or IFN-γ. J. Immunol. (1990) 145(3):865-872.
   PubMed Web of Science ®Google Scholar
• BENNETT BL, CRUZ R, LACSON RG, MANNING AM: Interleukin-4 suppression of tumor necrosis factor α-stimulated E-selectin gene transcription is mediated by STAT6 antagonism of NF-kappaB. J. Biol. Chem. (1997) 272(15):10212-10219.
   PubMed Web of Science ®Google Scholar
• CRONSTEIN BN, KIMMEL SC, LEVIN RI, MARTINIUK F, WEISSMANN G: A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc. Natl. Acad. Sci. USA (1992) 89(21):9991-9995.
   PubMed Web of Science ®Google Scholar
• BROSTJAN C, ANRATHER J, CSIZMADIA V, NATARAJAN G, WINKLER H: Glucocorticoids inhibit E-selectin expression by targeting NF-κB and not ATF/c-Jun. J. Immunol. (1997) 158(8):3836-3844.
   PubMed Web of Science ®Google Scholar
• ZHOU L, POPE BL, CHOURMOUZIS E, FUNG-LEUNG WP, LAU CY: Tepoxalin blocks neutrophil migration into cutaneous inflammatory sites by inhibiting Mac-1 and E-selectin expression. Eur. J. Immunol. (1996) 26(1):120-129.
   PubMed Web of Science ®Google Scholar
• LOU J, YTHIER A, BURGER D et al.: Modulation of soluble and membrane-bound TNF-induced phenotypic and functional changes of human brain microvascular endothelial cells by recombinant TNF binding protein I. J. Neuroimmunol. (1997) 77(1):107-115.
   PubMed Web of Science ®Google Scholar
• VANDERMEEREN M, JANSSENS S, BORGERS M, GEYSEN J: Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem. Biophys. Res. Commun. (1997) 234(1):19-23.
   PubMed Web of Science ®Google Scholar
• LOEWE R, PILLINGER M, DE MARTIN R et al.: Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-κB-dependent manner. J. Invest. Dermatol. (2001) 117(6):1363-1368.
   PubMed Web of Science ®Google Scholar
• ALTMEYER PJ, MATTHES U, PAWLAK F et al.: Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J. Am. Acad. Dermatol. (1994) 30(6):977-981.
   PubMed Web of Science ®Google Scholar
• MROWIETZ U, CHRISTOPHERS E, ALTMEYER P: Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br. J. Dermatol. (1998) 138(3):456-460.
   PubMed Web of Science ®Google Scholar
• HOEFNAGEL JJ, THIO HB, WILLEMZE R, BOUWES BAVINCK JN: Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br. J. Dermatol. (2003) 149(2):363-369.
   PubMed Web of Science ®Google Scholar
• MROWIETZ U, ASADULLAH K: Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol. Med. (2005) 11(1):43-48.
   PubMed Web of Science ®Google Scholar
• THOMSON AW, NALESNIK MA, RILO HR et al.: ICAM-1 and E-selectin expression in lesional biopsies of psoriasis patients responding to systemic FK 506 therapy. Autoimmunity (1993) 15(3):215-223.
   PubMed Web of Science ®Google Scholar
• GOMEZ-GAVIRO MV, DOMINGUEZ-JIMENEZ C, CARRETERO JM et al.: Down-regulation of L-selectin expression in neutrophils by nonsteroidal anti-inflammatory drugs: role of intracellular ATP concentration. Blood (2000) 96(10):3592-3600.
   PubMed Web of Science ®Google Scholar
• GOMEZ-GAVIRO MV, GONZALEZ-ALVARO I, DOMINGUEZ-JIMENEZ C et al.: Structure-function relationship and role of tumor necrosis factor-α-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs. J. Biol. Chem. (2002) 277(41):38212-38221.
   PubMed Web of Science ®Google Scholar
• HANDA K, IGARASHI Y, NISAR M, HAKOMORI S: Downregulation of GMP-140 (CD62 or PADGEM) expression on platelets by N,N-dimethyl and N,N,N-trimethyl derivatives of sphingosine. Biochemistry (1991) 30(50):11682-11686.
   PubMed Web of Science ®Google Scholar
• ZOLLNER TM, ASADULLAH K: Selectin and selectin ligand binding: a bittersweet attraction. J. Clin. Invest. (2003) 112(7):980-983.
   PubMed Web of Science ®Google Scholar
• BECKER DJ, LOWE JB: Fucose: biosynthesis and biological function in mammals. Glycobiology (2003) 13(7):41R-53R.
   PubMed Web of Science ®Google Scholar
• SMITHSON G, ROGERS CE, SMITH PL et al.: Fuc-TVII is required for T helper 1 and T cytotoxic 1 lymphocyte selectin ligand expression and recruitment in inflammation, and together with Fuc-TIV regulates naive T cell trafficking to lymph nodes. J. Exp. Med. (2001) 194(5):601-614.
   PubMed Web of Science ®Google Scholar
• MALY P, THALL A, PETRYNIAK B et al.: The α(1,3)fucosyltransferase Fuc-TVII controls leukocyte trafficking through an essential role in L-, E-, and P-selectin ligand biosynthesis. Cell (1996) 86(4):643-653.
   PubMed Web of Science ®Google Scholar
• GU YC, BAUER TR Jr, ACKERMANN MR et al.: The genetic immunodeficiency disease, leukocyte adhesion deficiency, in humans, dogs, cattle, and mice. Comp. Med. (2004) 54(4):363-372.
   PubMed Web of Science ®Google Scholar
• ETZIONI A, TONETTI M: Leukocyte adhesion deficiency II-from A to almost Z. Immunol. Rev. (2000) 178:138-147.
   PubMed Web of Science ®Google Scholar
• SCHOTTELIUS AJ, HAMANN A, ASADULLAH K: Role of fucosyltransferases in leukocyte trafficking: major impact for cutaneous immunity. Trends Immunol. (2003) 24(3):101-104.
   PubMed Web of Science ®Google Scholar
• COMPAIN P, MARTIN OR: Carbohydrate mimetics-based glycosyltransferase inhibitors. Bioorg. Med. Chem. (2001) 9(12):3077-3092.
   PubMed Web of Science ®Google Scholar
• LEE LV, MITCHELL ML, HUANG SJ et al.: A potent and highly selective inhibitor of human α-1,3-fucosyltransferase via click chemistry. J. Am. Chem. Soc. (2003) 125(32):9588-9589.
   PubMed Web of Science ®Google Scholar
• JEFFERIES I, BOWEN BR: Synthesis of inhibitors of α-1,3-fucosyltransferase. Bioorg. Med. Chem. Lett. (1997) 7(9):1171-1174.
   Web of Science ®Google Scholar
• WAKIMOTO T, MARUYAMA A, MATSUNAGA S et al.: Octa- and nonaprenylhydroquinone sulfates, inhibitors of α1,3-fucosyltransferase VII, from an Australian marine sponge Sarcotragus sp. Bioorg. Med. Chem. Lett (1999) 9(5):727-730.
   PubMed Web of Science ®Google Scholar
• BENGTSON P, LUNDBLAD A, LARSON G, PAHLSSON P: Polymorphonuclear leukocytes from individuals carrying the G329A mutation in the α 1,3-fucosyltransferase VII gene (FUT7) roll on E- and P-selectins. J. Immunol. (2002) 169(7):3940-3946.
   PubMed Web of Science ®Google Scholar
• DIMITROFF CJ, KUPPER TS, SACKSTEIN R: Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen. J. Clin. Invest. (2003) 112(7):1008-1018.
   PubMed Web of Science ®Google Scholar
• DIMITROFF CJ, BERNACKI RJ, SACKSTEIN R: Glycosylation-dependent inhibition of cutaneous lymphocyte-associated antigen expression: implications in modulating lymphocyte migration to skin. Blood (2003) 101(2):602-610.
   PubMed Web of Science ®Google Scholar
• YAMADA H, SHIOMI K, XU Q et al.: New glycosidases inhibitors, panosialins D and wD produced by Streptomyces sp. OH-5186. J. Antibiot. (Tokyo) (1995) 48(3):205-210.
   PubMed Web of Science ®Google Scholar
• SHINODA K, SHITARA K, YOSHIHARA Y et al.: Panosialins, inhibitors of an α1,3-fucosyltransferase Fuc-TVII, suppress the expression of selectin ligands on U937 cells. Glycoconj. J. (1998) 15(11):1079-1083.
   PubMed Web of Science ®Google Scholar
• UCHIMURA K, GAUGUET JM, SINGER MS et al.: A major class of L-selectin ligands is eliminated in mice deficient in two sulfotransferases expressed in high endothelial venules. Nat. Immunol. (2005) 6(11):1105-1113.
   PubMed Web of Science ®Google Scholar
• JOHNSTON A, GUDJONSSON JE, SIGMUNDSDOTTIR H, LUDVIKSSON BR, VALDIMARSSON H: The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin. Immunol. (2005) 114(2):154-163.
   PubMed Web of Science ®Google Scholar
• ELLIOTT PJ, ZOLLNER TM, BOEHNCKE WH: Proteasome inhibition: a new anti-inflammatory strategy. J. Mol. Med. (2003) 81(4):235-245.
   PubMed Web of Science ®Google Scholar
• SOUCY F, GRENIER L, BEHNKE ML et al.: A novel and efficient synthesis of a highly active analogue of clasto-lactacystin lactone. J. Am. Chem. Soc. (1999) 121:9967-9976.
   Web of Science ®Google Scholar
• ZOLLNER TM, PODDA M, PIEN C et al.: Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J. Clin. Invest. (2002) 109(5):671-679.
   PubMed Web of Science ®Google Scholar
• SHAH IM, LEES KR, PIEN CP, ELLIOTT PJ: Early clinical experience with the novel proteasome inhibitor PS-519. Br. J. Clin. Pharmacol. (2002) 54(3):269-276.
   Web of Science ®Google Scholar
• DI NAPOLI M, PAPA F: MLN-519. Millennium/PAION. Curr. Opin. Investig. Drugs (2003) 4(3):333-341.
   PubMedGoogle Scholar
• ISSEKUTZ AC, ISSEKUTZ TB: The role of E-selectin, P-selectin, and very late activation antigen-4 in T lymphocyte migration to dermal inflammation. J. Immunol. (2002) 168(4):1934-1939.
   PubMed Web of Science ®Google Scholar
• JUTILA MA, WATTS G, WALCHECK B, KANSAS GS: Characterization of a functionally important and evolutionarily well-conserved epitope mapped to the short consensus repeats of E-selectin and L-selectin. J. Exp. Med. (1992) 175(6):1565-1573.
   PubMed Web of Science ®Google Scholar
• BARGATZE RF, KURK S, WATTS G et al.: In vivo and in vitro functional examination of a conserved epitope of L- and E-selectin crucial for leukocyte-endothelial cell interactions. J. Immunol. (1994) 152(12):5814-5825.
   PubMed Web of Science ®Google Scholar
• BERG EL, FROMM C, MELROSE J, TSURUSHITA N: Antibodies cross-reactive with E- and P-selectin block both E- and P-selectin functions. Blood (1995) 85(1):31-37.
   PubMed Web of Science ®Google Scholar
• HE XY, XU Z, MELROSE J et al.: Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin. J. Immunol. (1998) 160(2):1029-1035.
   PubMed Web of Science ®Google Scholar
• HARDTKE M, FRIEDRICH M, PHILIPP S et al.: Anti-L-selectin therapy is not effective in psoriasis: a randomized trial. Arch. Dermatol. Res. (2005) 296:427.
   Google Scholar
• BHUSHAN M, BLEIKER TO, BALLSDON AE et al.: Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br. J. Dermatol. (2002) 146(5):824-831.
   PubMed Web of Science ®Google Scholar
• SAKO D, COMESS KM, BARONE KM et al.: A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding. Cell (1995) 83(2):323-331.
   PubMed Web of Science ®Google Scholar
• BRIGGS JB, ODA Y, GILBERT JH, SCHAEFER ME, MACHER BA: Peptides inhibit selectin-mediated cell adhesion in vitro, and neutrophil influx into inflammatory sites in vivo. Glycobiology (1995) 5(6):583-588.
   PubMed Web of Science ®Google Scholar
• HICKE BJ, WATSON SR, KOENIG A et al.: DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice. J. Clin. Invest. (1996) 98(12):2688-2692.
   PubMed Web of Science ®Google Scholar
• Cytel shuts down after lead drug fails again. Bio World Week (1999) 7(14).
   Google Scholar
• KERR KM, AUGER WR, MARSH JJ et al.: The use of cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy. Am. J. Respir. Crit. Care Med. (2000) 162(1):14-20.
   PubMed Web of Science ®Google Scholar
• THOMA G, MAGNANI JL, PATTON JT: Synthesis and biological evaluation of a sialyl Lewis X mimic with significantly improved E-selectin inhibition. Bioorg. Med. Chem. Lett (2001) 11(7):923-925.
   PubMed Web of Science ®Google Scholar
• BIEDERMANN T, SCHWARZLER C, LAMETSCHWANDTNER G et al.: Targeting CLA/E-selectin interactions prevents CCR4-mediated recruitment of human Th2 memory cells to human skin in vivo. Eur. J. Immunol. (2002) 32(11):3171-3180.
   PubMed Web of Science ®Google Scholar
• ARUFFO A, KOLANUS W, WALZ G, FREDMAN P, SEED B: CD62/P-selectin recognition of myeloid and tumor cell sulfatides. Cell (1991) 67(1):35-44.
   PubMed Web of Science ®Google Scholar
• NAIR X, TODDERUD G, DAVERN L et al.: Inhibition of immune complex induced inflammation by a small molecular weight selectin antagonist. Mediators Inflamm. (1994) 3:459-463
   PubMed Web of Science ®Google Scholar
• TODDERUD G, NAIR X, LEE D et al.: BMS-190394, a selectin inhibitor, prevents rat cutaneous inflammatory reactions. J. Pharmacol. Exp. Ther. (1997) 282(3):1298-1304.
   PubMed Web of Science ®Google Scholar
• YAMASHIRO K, KIRYU J, TSUJIKAWA A et al.: Suppressive effects of selectin inhibitor SKK-60060 on the leucocyte infiltration during endotoxin induced uveitis. Br. J. Ophthalmol. (2003) 87(4):476-480.
   PubMed Web of Science ®Google Scholar
• TSUKIDA T, MORIYAMA H, KUROKAWA K et al.: Studies on selectin blockers. 7. Structure-activity relationships of sialyl Lewis X mimetics based on modified Ser-Glu dipeptides. J. Med. Chem. (1998) 41(22):4279-4287.
   PubMed Web of Science ®Google Scholar
• TSUJISHITA H, HIRAMATSU Y, KONDO N et al.: Selectin-ligand interactions revealed by molecular dynamics simulation in solution. J. Med. Chem. (1997) 40(3):362-369.
   PubMed Web of Science ®Google Scholar
• WADA Y, MATSUDA N, SAITO T et al.: Effect of GSC-150, a new synthetic selectin inhibitor, on skin inflammation in mice. Jpn J. Pharmacol. (1996) 71(Suppl. 1):.
   Google Scholar
• KAILA N, THOMAS BET, THAKKER P et al.: Design and synthesis of sialyl Lewis x mimics as E-selectin inhibitors. Bioorg. Med. Chem. Lett. (2001) 11(2):151-155.
   PubMed Web of Science ®Google Scholar
• KAILA N, SOMERS WS, THOMAS BE et al.: Quinic acid derivatives as sialyl Lewisx-mimicking selectin inhibitors: design, synthesis, and crystal structure in complex with E-selectin. J. Med. Chem. (2005) 48(13):4346-4357.
   PubMed Web of Science ®Google Scholar
• IKEGAMI-KUZUHARA A, YOSHINAKA T, OHMOTO H, INOUE Y, SAITO T: Therapeutic potential of a novel synthetic selectin blocker, OJ-R9188, in allergic dermatitis. Br. J. Pharmacol. (2001) 134(7):1498-1504.
   PubMed Web of Science ®Google Scholar
• SCHON MP, KRAHN T, SCHON M et al.: Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat. Med. (2002) 8(4):366-372.
   PubMed Web of Science ®Google Scholar
• WIENRICH BG, KRAHN T, SCHON M et al.: Structure–function relation of efomycines, a family of small-molecule inhibitors of selectin functions. J. Invest. Dermatol. (2006) 126(4):882-889.
   PubMed Web of Science ®Google Scholar
• OOSTINGH GJ, ENDERS S, GRÜNER S et al.: Efomycin M, a novel anti-inflammatory agent, can inhibit L-selectin mediated leukocyte interactions. Immunobiol. (2004) 209(4-6):313.
   Google Scholar
• KOGAN TP, DUPRE B, BUI H et al.: Novel synthetic inhibitors of selectin-mediated cell adhesion: synthesis of 1,6-bis[3-(3-carboxymethylphenyl)-4- (2-α-D-mannopyranosyloxy)phenyl]hexane (TBC1269). J. Med. Chem. (1998) 41(7):1099-1111.
   PubMed Web of Science ®Google Scholar
• KOGAN TP, DUPRE B, KELLER KM et al.: Rational design and synthesis of small molecule, non-oligosaccharide selectin inhibitors: (α-D-mannopyranosyloxy)- biphenyl-substituted carboxylic acids. J. Med. Chem. (1995) 38(26):4976-4984.
   PubMed Web of Science ®Google Scholar
• AYDT E, WOLFF G: Development of synthetic pan-selectin antagonists: a new treatment strategy for chronic inflammation in asthma. Pathobiology (2002) 70(5):297-301.
   PubMed Web of Science ®Google Scholar
• FRIEDRICH M, BOCK D, PHILIPP S et al.: Pan-selectin antagonism improves psoriasis manifestation in mice and man. Arch. Dermatol. Res. (2005):1-7.
   Google Scholar
• FRIEDRICH M, VOLLHARDT K, ZAHLTEN R, STERRY W, WOLFF G: Demonstration of antipsoriatic efficacy of a new topical formulation of the small molecule selectin antagonist bimosiamose. European Congress on Psoriasis, Paris, France (2004).
   Google Scholar
• MEYER M, JILMA B, ZAHLTEN R, WOLFF G: Physiochemical properties, safety and pharmacokinetics of bimosiamose for intravenous administration. J. Clin. Pharm. Ther. (2005) 43:463-471.
   Web of Science ®Google Scholar
• SHEAR NH: Fulfilling an unmet need in psoriasis : do biologicals hold the key to improved tolerability? Drug Saf. (2006) 29(1):49-66.
   PubMed Web of Science ®Google Scholar
• PEARCE DJ, NELSON AA, FLEISCHER AB, BALKRISHNAN R, FELDMAN SR: The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J. Dermatol. Treat. (2006) 17(1):29-37.
   PubMed Web of Science ®Google Scholar
• BEEH KM, BEIER J, MEYER M et al.: Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulm. Pharmacol. Ther. (2005) 19(4):233-41.
   PubMed Web of Science ®Google Scholar